Eagle Pharmaceuticals Stock Forecast, Price & News

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

Is Eagle Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Eagle Pharmaceuticals stock.
View analyst ratings for Eagle Pharmaceuticals or view top-rated stocks.

How has Eagle Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EGRX shares have increased by 19.7% and is now trading at $46.76.
View which stocks have been most impacted by COVID-19.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Eagle Pharmaceuticals.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to analysts' expectations of $46.70 million. Eagle Pharmaceuticals had a trailing twelve-month return on equity of 2.97% and a net margin of 3.14%. During the same period in the prior year, the company posted $0.51 earnings per share.
View Eagle Pharmaceuticals' earnings history.

What price target have analysts set for EGRX?

2 analysts have issued 1-year price targets for Eagle Pharmaceuticals' shares. Their forecasts range from $51.00 to $51.00. On average, they expect Eagle Pharmaceuticals' share price to reach $51.00 in the next year. This suggests a possible upside of 9.1% from the stock's current price.
View analysts' price targets for Eagle Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the following people:

• Scott L. Tarriff, President, Chief Executive Officer & Director
• Michael Moran, Executive VP, Chief Operating & Commercial Officer
• Brian Cahill, Chief Financial Officer
• Daniel O'Connor, Chief Strategy Officer
• David M. Pernock, Executive Vice President-Operations

Who are some of Eagle Pharmaceuticals' key competitors?

Some companies that are related to Eagle Pharmaceuticals include Sage Therapeutics (SAGE), I-Mab (IMAB), Indivior (INVVY), Arcus Biosciences (RCUS), EQRx (EQRX), Nuvation Bio (NUVB), Aurinia Pharmaceuticals (AUPH), Nektar Therapeutics (NKTR), Xencor (XNCR), Corcept Therapeutics (CORT), Harmony Biosciences (HRMY), Cryoport (CYRX), Schrödinger (SDGR), TG Therapeutics (TGTX) and Ligand Pharmaceuticals (LGND).
View all of EGRX's competitors.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Scout Investments Inc. (1.31%), Russell Investments Group Ltd. (0.10%), State of Alaska Department of Revenue (0.06%) and Cutler Group LP (0.01%).
View institutional ownership trends for Eagle Pharmaceuticals.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Scout Investments Inc., and State of Alaska Department of Revenue.
View insider buying and selling activity for Eagle Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was acquired by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Eagle Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $46.76.

How much money does Eagle Pharmaceuticals make?

Eagle Pharmaceuticals has a market capitalization of $603.86 million and generates $187.80 million in revenue each year. The specialty pharmaceutical company earns $11.99 million in net income (profit) each year or $0.41 on an earnings per share basis.

How many employees does Eagle Pharmaceuticals have?

Eagle Pharmaceuticals employs 106 workers across the globe.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is www.eagleus.com.

Where are Eagle Pharmaceuticals' headquarters?

Eagle Pharmaceuticals is headquartered at 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at (201) 326-5300 or via email at [email protected].